Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abraham Avigdor

Showing results (31-40 of 118) with videos related to

Pageof 12
Sort By:
Blood|June 9, 2005
Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric miceSigal Tavor, Isabelle Petit, Svetlana Porozov, et al.
Leukemia & Lymphoma|January 18, 2014
Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?Meirav Kedmi, Irit Avivi, Elena Ribakovsky, et al.
Blood Cells, Molecules & Diseases|April 3, 2017
Thrombin generation as a predictor of thromboembolic events in multiple myeloma patientsMerav Leiba, Sarah Malkiel, Ivan Budnik, et al.
Ejhaem|July 18, 2022
First-line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomesAbraham Avigdor, Fabrizio Trinchese, Francois Gavini, et al.
Experimental Hematology|September 14, 2011
CD45 regulates homing and engraftment of immature normal and leukemic human cells in transplanted immunodeficient miceShoham Shivtiel, Kfir Lapid, Vyacheslav Kalchenko, et al.
Plos One|May 1, 2023
Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disordersHila Magen, Abraham Avigdor, Lee Nevo, et al.
Oncotarget|September 11, 2016
The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivoGabriela Rozic, Lena Paukov, Jana Jakubikova, et al.
Acta Haematologica|November 21, 2015
High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT ScanMeirav Kedmi, Arie Apel, Tima Davidson, et al.
The Israel Medical Association Journal : IMAJ|May 20, 2014
Outcome differences in patients with precursor B cell acute lymphocytic leukemia over time: a retrospective analysisArie Apel, Meirav Kedmi, Etai Levi, et al.
Harefuah|April 15, 2024
[CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T CELLS) THERAPY FOR B-CELL HEMATOLOGICAL MALIGNANCIES - FROM THE ISRAELI SOCIETY OF HEMATOLOGY AND TRANSFUSION MEDICINE]Uri Greenbaum, Dana Yehudai-Ofir, Ofrat Beyar Katz, et al.
Pageof 12

Showing results (31-40 of 118) with videos related to

Sort By:
Pageof 12
Blood|June 9, 2005
Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric miceSigal Tavor, Isabelle Petit, Svetlana Porozov, et al.
Leukemia & Lymphoma|January 18, 2014
Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?Meirav Kedmi, Irit Avivi, Elena Ribakovsky, et al.
Blood Cells, Molecules & Diseases|April 3, 2017
Thrombin generation as a predictor of thromboembolic events in multiple myeloma patientsMerav Leiba, Sarah Malkiel, Ivan Budnik, et al.
Ejhaem|July 18, 2022
First-line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomesAbraham Avigdor, Fabrizio Trinchese, Francois Gavini, et al.
Experimental Hematology|September 14, 2011
CD45 regulates homing and engraftment of immature normal and leukemic human cells in transplanted immunodeficient miceShoham Shivtiel, Kfir Lapid, Vyacheslav Kalchenko, et al.
Plos One|May 1, 2023
Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disordersHila Magen, Abraham Avigdor, Lee Nevo, et al.
Oncotarget|September 11, 2016
The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivoGabriela Rozic, Lena Paukov, Jana Jakubikova, et al.
Acta Haematologica|November 21, 2015
High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT ScanMeirav Kedmi, Arie Apel, Tima Davidson, et al.
The Israel Medical Association Journal : IMAJ|May 20, 2014
Outcome differences in patients with precursor B cell acute lymphocytic leukemia over time: a retrospective analysisArie Apel, Meirav Kedmi, Etai Levi, et al.
Harefuah|April 15, 2024
[CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T CELLS) THERAPY FOR B-CELL HEMATOLOGICAL MALIGNANCIES - FROM THE ISRAELI SOCIETY OF HEMATOLOGY AND TRANSFUSION MEDICINE]Uri Greenbaum, Dana Yehudai-Ofir, Ofrat Beyar Katz, et al.
Pageof 12